Cytokeratin 18 fragment is associated with steatosis-associated fibrosis estimator score and lipid in patients with steatotic liver disease

Figure 4 Criteria for high triglycerides (≥ 126 mg/dL) and low high-density lipoprotein (≤ 56 mg/dL) have more effect on high cytokeratin 18 fragment than the settings for high/treatment triglycerides (≥ 150 mg/dL or lipid-lowering treatment) and low/treatment high-density lipoprotein (≤ 39 mg/dL for men and 50 mg/dL for women or lipid-lowering treatment). A: Effect of high triglycerides (TGs) (≥ 126 mg/dL), low high-density lipoprotein (HDL) (≤ 56 mg/dL), high/treatment TG (≥ 150 mg/dL or lipid-lowering treatment), and low/treatment HDL (39 mg/dL in men and ≤ 50 mg/dL in women or lipid-lowering treatment) on high cytokeratin 18 fragment (CK18F) was investigated using multivariate logistic regression analysis; B: Effect of high TG (≥ 126 mg/dL), low HDL (≤ 56 mg/dL), and high TG and low HDL on high CK18F was evaluated using multivariate logistic regression analysis; C: The criteria for high TG and low HDL in cardiometabolic risk factor (CMRF) were replaced by TG ≥ 126 mg/dL and HDL < 56 mg/dL in modified CMRF (mCMRF), and the effect of CMRF and mCMRF on high CK18F was evaluated using multivariate logistic regression analysis. OR: Odds ratio; TGHHDLL: Triglycerides high (> 126 mg/dL) and high-density lipoprotein low (≤ 56 mg/dL).